MIT has entered a collaborative partnership with Sigilon Therapeutics to create programmable cell therapeutics to treat chronic illnesses and diseases such as hemophilia and lysosomal storage diseases.
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information
that is changing your industry today, hand-curated by our professional editors from
thousands of sources and delivered straight to your inbox.